Security Intelligence

Pharmaceutical Supply Chain Security | CloseProtectionHire

Q: "What are the main theft and diversion risks in pharmaceutical supply chains?"

"The three primary theft and diversion risks in pharmaceutical supply chains are: product theft from distribution centres, warehouses, or in-transit vehicles (particularly for high-value antiretrovirals, oncology drugs, and weight-loss medications); cold chain compromise that creates product degraded to near-zero therapeutic value but still diverted into the grey market; and organised counterfeit infiltration at the wholesale distribution tier. TAPA (Transported Asset Protection Association) data from 2024 identifies pharmaceuticals as the second most stolen cargo category in EMEA after electronics. Organised theft groups specifically target chilled pharmaceutical cargo because cold-chain products command premium prices on the grey market."

Q: "What is the threat from counterfeit medicines entering the legitimate supply chain?"

"Counterfeit medicines entering the legitimate pharmaceutical supply chain is the highest-consequence supply chain security risk in the sector. WHO estimates that 1 in 10 medical products in low and middle-income countries is either substandard or falsified. INTERPOL Operation Pangea (annual coordinated enforcement action) reported seizure of over 500 million illicit doses across 122 countries in the 2023 operation. The infiltration mechanism is typically through unregulated wholesale intermediaries -- secondary wholesalers who buy out-of-specification or grey-market product and introduce it to the legitimate distribution chain with falsified documentation."

Q: "What TAPA standards apply to pharmaceutical in-transit security?"

"TAPA (Transported Asset Protection Association) publishes the Freight Security Requirements (FSR) and Trucking Security Requirements (TSR) standards that apply to high-value cargo, including pharmaceuticals. For temperature-sensitive pharmaceutical cargo, the TAPA Cold Chain Security Standard (CCSS) -- published in 2023 -- establishes baseline requirements for: vehicle GPS tracking, remote temperature monitoring with tamper evidence, secure vehicle parking protocols, driver vetting and background checks, and incident reporting thresholds. Pharmaceutical manufacturers and distributors operating in P1 markets should require TAPA FSR certification from their 3PL and distribution partners."

Q: "How should a pharmaceutical company protect clinical trial material in transit in high-risk cities?"

"Clinical trial material (CTM) in transit in P1 cities requires a security standard above standard pharmaceutical distribution because CTM typically has a much smaller replacement supply, a hard deadline (trial dosing schedule), and sometimes an irreplaceable unique formulation for an active trial. The minimum security standard for CTM in P1 cities is: temperature-monitored vehicle with real-time GPS, a dedicated security escort vehicle or close protection officer for the transit, a cover story for the cargo (unmarked outer packaging, no pharmaceutical labelling on the vehicle), and a pre-vetted handover protocol at the receiving site. A single diversion or theft incident can halt an active clinical trial."

Q: "What regulatory requirements apply to pharmaceutical supply chain security?"

"UK pharmaceutical supply chains are governed by MHRA Good Distribution Practice (GDP) guidelines (transposing EU GDP 2013/C 343/01 for UK operations post-Brexit). GDP requires: appropriately secure storage and transport, temperature monitoring throughout the cold chain with data logging available for regulatory inspection, documented procedures for handling temperature excursions, qualification of transportation providers, and investigation and reporting requirements for any supply chain incidents. In the US, DSCSA (Drug Supply Chain Security Act) requires serialisation and track-and-trace for prescription drugs through all tiers of the supply chain. In practice, GDP and DSCSA together set the baseline for most multinational pharmaceutical supply chains."

Security for pharmaceutical supply chains: cold chain protection, counterfeit medicine infiltration, INTERPOL Operation Pangea, clinical trial material transit, and drug theft prevention in high-risk markets.

4 May 2026

Written by James Whitfield

Speak to the Team

Pharmaceutical supply chains operate in the same physical security environment as any other high-value cargo movement – but with specific characteristics that make the security failure modes more consequential. A stolen consignment of electronics is a financial loss. A diverted pharmaceutical consignment that enters the grey market may harm patients. A cold chain excursion that degrades product undetected has the same patient safety implication.

This assessment covers the security risks specific to pharmaceutical supply chains, the organised crime and counterfeit infiltration threat, the regulatory requirements that create a compliance baseline, and the operational standards required for high-risk market distribution and clinical trial material transit.

The Theft Threat

TAPA EMEA Incident Reports (published quarterly) consistently identify pharmaceuticals as the second most targeted cargo category in Europe, the Middle East, and Africa. The 2023 TAPA EMEA report recorded 222 pharmaceutical theft incidents in the EMEA region, with total value of stolen product estimated at over EUR 85 million. The majority of incidents occurred at distribution and warehouse facilities rather than in-transit – though in-transit incidents in P1 cities represented the highest-average-value incidents by consignment.

The theft threat breaks down into three categories:

Organised professional theft: Coordinated theft from distribution facilities by organised groups with inside information. The inside-knowledge element is consistent across the majority of high-value pharmaceutical thefts investigated by law enforcement. Employee background screening, access control logging, and insider threat awareness programmes are the primary countermeasures.

In-transit robbery: Targeted robbery of pharmaceutical delivery vehicles, most prevalent in P1 cities with weak cargo security regulation – Lagos, Karachi, Manila, Jakarta. The targeting mechanism is typically operational intelligence about the consignment from the distribution facility. Unmarked vehicles, cover packaging, variable route selection, and last-mile security escorts are standard countermeasures.

Cold chain diversion: Planned diversion of cold chain consignments to unregulated storage followed by resale into the grey market. The physical product arrives intact but the cold chain record shows an excursion that the distributor reports as “in tolerance.” Real-time independent temperature monitoring – with data held by the shipper, not the carrier – is the countermeasure.

The Counterfeit Infiltration Threat

WHO estimates that 1 in 10 medical products in low and middle-income countries is substandard or falsified. In high-income markets the proportion is lower but not zero – the 2024 US FDA DSCSA enforcement report identified 14 counterfeit product recalls from the US market in the 2023 reporting period.

INTERPOL’s Operation Pangea – the annual coordinated enforcement action on pharmaceutical crime, running since 2008 – provides the clearest picture of current infiltration methods. Pangea XVI (2023) coordinated enforcement across 122 countries and seized:

Over 500 million illicit doses
11,000+ websites and online platforms shut down or flagged
Counterfeit oncology, weight-loss (GLP-1 agonists), and erectile dysfunction medications as the three highest-volume categories
EUR 10 million in transaction value disrupted

The infiltration mechanism into the legitimate supply chain is consistently at the secondary wholesale tier. Primary manufacturers and tier-1 distributors operate under regulatory oversight with documented quality systems. Secondary wholesalers – who buy product from multiple sources including grey market and out-of-specification surplus – have historically been the entry point for counterfeit infiltration.

Supplier qualification as a security control: MHRA GDP guidelines and US DSCSA both require qualification of all supply chain partners. In practice, many pharmaceutical companies conduct rigorous GDP audits of primary distribution partners and cursory checks of secondary wholesalers. A quarterly re-qualification process for all wholesale intermediaries, with specific counterfeit product screening controls, is the current best practice standard.

Serialisation and track-and-trace: DSCSA mandated product-level serialisation for the US market from November 2023. EU Falsified Medicines Directive (FMD) mandated pack-level unique identifiers for the EU market from February 2019. Both frameworks provide the technical architecture for detecting counterfeit infiltration at the point of sale. The practical limitation is enforcement at the secondary wholesale tier in markets where regulatory oversight is limited.

Cold Chain Security

Temperature-sensitive pharmaceutical products – biologics, vaccines, insulin, some oncology drugs, and since 2023 the GLP-1 weight-loss medication category – require continuous cold chain maintenance from manufacturer to patient. A cold chain excursion (temperature outside the specified range) can degrade the product to therapeutic inefficacy while leaving it visually indistinguishable from in-specification product.

The cold chain security stack is:

Logistics qualification: GDP Article 9 requires qualification of all transportation and storage providers. TAPA’s Cold Chain Security Standard (CCSS, 2023) establishes specific requirements for temperature-monitored vehicles, driver training, secure parking protocols, and incident reporting. Requiring CCSS certification from 3PL partners in high-risk markets is the current industry standard for multinational pharmaceutical manufacturers.

Independent monitoring: Temperature data should be held by the shipper independently of the carrier. Real-time GPS-enabled temperature loggers (companies including Sensitech, Emerson, and Berlinger supply this equipment) provide shipper-side data that cannot be altered by the carrier. Where a carrier’s documentation shows an in-tolerance result and the independent shipper-side data shows an excursion, the independent data takes precedence for product release decisions.

P1 city last-mile specific requirements: Last-mile distribution in Lagos, Karachi, Manila, and Jakarta presents specific cold chain security challenges: unreliable refrigerated vehicle availability, informal last-mile distribution sub-contracting, and high ambient temperatures that accelerate cold chain failure if a break occurs. Pre-qualifying a last-mile distribution partner in each P1 market, conducting temperature mapping of their vehicles and storage facilities before use, and requiring real-time data access during any P1 city last-mile delivery is the minimum standard.

Clinical Trial Material in Transit

Clinical trial material (CTM) has characteristics that make supply chain security failure categorically more serious than a standard pharmaceutical distribution incident:

Irreplaceability: CTM for an active trial is often produced in small quantities, with no readily available replacement stock. A single theft or cold chain compromise may not be replaceable within the trial’s dosing schedule.

Trial continuity: A CTM diversion or loss in a P1 city can halt participant dosing and, in a time-critical trial, may require protocol deviation reporting to the ethics committee and regulatory authority.

Comparator and blinding risk: For blinded studies, CTM compromise that reveals the blinding – for example, through chain of custody documentation that identifies active versus placebo consignments – creates a protocol integrity risk that may invalidate the trial.

The CTM transit security framework for P1 cities should include: double-blind manifest documentation (product described by code reference only, not by therapeutic name), dedicated security escort vehicle or CP officer for any transit above a defined value threshold, a pre-agreed cover story for the cargo, and a vetted handover protocol at the receiving site with dual-signature chain of custody confirmation.

For the broader security framework applicable to high-value cargo in P1 markets, see our high-value asset protection and transport guide. For security due diligence on pharmaceutical supply chain partners specifically, see our security due diligence for business partnerships guide.

Sources

TAPA EMEA Incident Report 2023/2024. WHO: A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products 2022. INTERPOL Operation Pangea XVI Report 2023. MHRA Good Distribution Practice Guidelines 2024. EU GDP Guidelines 2013/C 343/01 (UK transposition). US FDA DSCSA: Drug Supply Chain Security Act Enforcement Report 2024. EU Falsified Medicines Directive 2011/62/EU. TAPA Cold Chain Security Standard (CCSS) 2023. Control Risks: Pharmaceutical and Life Sciences Risk Report 2024. OSAC: Pharmaceutical Sector Security Guidance 2024. ICC Commercial Crime Services: Cargo Crime Report 2024. ACFE (Association of Certified Fraud Examiners): Pharmaceutical Sector Fraud Report 2023. Sensitech/Emerson Cold Chain Market Report 2024.

James Whitfield is a Senior Security Consultant with 20 years of experience in corporate security, supply chain risk, and high-value asset protection across global pharmaceutical operations.

Summary

Key takeaways

Counterfeit medicine infiltration occurs at the wholesale tier -- not the manufacturing tier

Pharmaceutical manufacturers invest heavily in product security at the factory. The infiltration point is almost always the secondary wholesale or distribution tier -- intermediaries who buy grey-market or diverted product and introduce it to the legitimate chain through falsified documentation. Supplier qualification and audit programmes must extend to all wholesale intermediaries, not just tier-1 distribution partners.

Cold chain compromise is more common than product theft -- and equally serious

A cold chain excursion that renders a consignment therapeutically worthless but physically intact creates product that enters the grey market at full visual specification. Temperature-monitored cold chain with tamper-evident sealing and real-time data logging is a supply chain security control, not just a quality management requirement.

P1 city last-mile distribution is the highest-risk phase of the pharmaceutical supply chain

Organised criminal theft groups specifically target last-mile distribution in cities where the regulatory environment for cargo security is weak. Lagos, Jakarta, Manila, and Karachi each have documented pharmaceutical theft incidents at the last-mile stage. Pre-vetted, TAPA-compliant distribution partners in P1 cities are a supply chain security baseline, not a premium option.

INTERPOL Operation Pangea provides annual intelligence on counterfeit infiltration methods

INTERPOL's annual Pangea operation coordinating enforcement across 100+ countries produces a public report identifying current counterfeit medicine typologies, source countries, and distribution methods. The Pangea 2023 report (released 2024) identified significant growth in online pharmacy and social media-enabled distribution of falsified weight-loss medications and oncology drugs. Pharmaceutical security teams should treat the annual Pangea report as an intelligence input for their threat model.

Clinical trial material requires a security standard above standard pharmaceutical distribution

CTM has characteristics that make theft or diversion a critical incident rather than a reportable loss: small replacement supply, irreplaceable formulation, hard trial timeline. A single in-transit incident in a P1 city can halt an active trial. CTM consignments in P1 markets should be treated as high-value cargo requiring dedicated security escort, not as routine pharmaceutical distribution.

FAQ

Frequently Asked Questions

The three primary theft and diversion risks in pharmaceutical supply chains are: product theft from distribution centres, warehouses, or in-transit vehicles (particularly for high-value antiretrovirals, oncology drugs, and weight-loss medications); cold chain compromise that creates product degraded to near-zero therapeutic value but still diverted into the grey market; and organised counterfeit infiltration at the wholesale distribution tier. TAPA (Transported Asset Protection Association) data from 2024 identifies pharmaceuticals as the second most stolen cargo category in EMEA after electronics. Organised theft groups specifically target chilled pharmaceutical cargo because cold-chain products command premium prices on the grey market.

Counterfeit medicines entering the legitimate pharmaceutical supply chain is the highest-consequence supply chain security risk in the sector. WHO estimates that 1 in 10 medical products in low and middle-income countries is either substandard or falsified. INTERPOL Operation Pangea (annual coordinated enforcement action) reported seizure of over 500 million illicit doses across 122 countries in the 2023 operation. The infiltration mechanism is typically through unregulated wholesale intermediaries – secondary wholesalers who buy out-of-specification or grey-market product and introduce it to the legitimate distribution chain with falsified documentation.

TAPA (Transported Asset Protection Association) publishes the Freight Security Requirements (FSR) and Trucking Security Requirements (TSR) standards that apply to high-value cargo, including pharmaceuticals. For temperature-sensitive pharmaceutical cargo, the TAPA Cold Chain Security Standard (CCSS) – published in 2023 – establishes baseline requirements for: vehicle GPS tracking, remote temperature monitoring with tamper evidence, secure vehicle parking protocols, driver vetting and background checks, and incident reporting thresholds. Pharmaceutical manufacturers and distributors operating in P1 markets should require TAPA FSR certification from their 3PL and distribution partners.

Clinical trial material (CTM) in transit in P1 cities requires a security standard above standard pharmaceutical distribution because CTM typically has a much smaller replacement supply, a hard deadline (trial dosing schedule), and sometimes an irreplaceable unique formulation for an active trial. The minimum security standard for CTM in P1 cities is: temperature-monitored vehicle with real-time GPS, a dedicated security escort vehicle or close protection officer for the transit, a cover story for the cargo (unmarked outer packaging, no pharmaceutical labelling on the vehicle), and a pre-vetted handover protocol at the receiving site. A single diversion or theft incident can halt an active clinical trial.

UK pharmaceutical supply chains are governed by MHRA Good Distribution Practice (GDP) guidelines (transposing EU GDP 2013/C 343/01 for UK operations post-Brexit). GDP requires: appropriately secure storage and transport, temperature monitoring throughout the cold chain with data logging available for regulatory inspection, documented procedures for handling temperature excursions, qualification of transportation providers, and investigation and reporting requirements for any supply chain incidents. In the US, DSCSA (Drug Supply Chain Security Act) requires serialisation and track-and-trace for prescription drugs through all tiers of the supply chain. In practice, GDP and DSCSA together set the baseline for most multinational pharmaceutical supply chains.

Get in Touch

Request a Consultation

Describe your security requirements below. All enquiries are confidential and handled by licensed consultants.